LBNL Logo ONHS Funding Opportunity Report
Navigator Dashboard Interactive Graph Global Graph Subscribe

DoW Parkinson’s, Early Investigator Research Award

Solicitation ID: HT942526PRPEIRA

Agency: DHA

Type: Grant
Deadline: 2026-11-06T00:00:00 ET
Eligibility: Yes (Unrestricted)
Funding: Approximately $4.2M total to fund about seven awards, with cost caps of $0.3M for Funding Level 1 and $1.0M for Funding Level 2.
Doc Type: BAA
Clearance: No
Program Manager: help@eBRAP.org
Last Updated: 2026-08-19 14:43
Analyzed File: HT942526PRPEIRA_GG.pdf

Eligibility Reasoning

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities... Applications... involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged.

Note: This is an AI-generated summary...

Summary

The Fiscal Year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson's disease (PD) research by early-career investigators to benefit Service Members, Veterans, and their families. The award offers two distinct funding levels. Funding Level 1 is for postdoctoral or clinical fellows, requires a mentor, has a total cost cap of $0.3M, and does not require preliminary data. Funding Level 2 is for early-career independent investigators (within 10 years of their advanced degree), does not require a mentor, has a total cost cap of $1.0M, and requires preliminary data. The maximum period of performance for both levels is 2 years. All projects must address at least one of four FY26 PRP Focus Areas: PD heterogeneity, in vitro models, biological mechanisms/biomarkers of unmet needs, or interventions for unmet needs. Clinical trials are not allowed.

Overall Technical Areas

Parkinson's Disease HeterogeneityClinical Course AnalysisIn Vitro Disease ModelingBiological Mechanisms of PDBiomarker Discovery and ValidationNeuroimaging TechniquesNon-Motor Symptom ResearchMotor Symptom ResearchPharmacological InterventionsNon-Pharmacological InterventionsCentral Nervous System StimulationPreclinical Therapeutic ModelsAnimal Models of NeurodegenerationBiostatistical Analysis and Modeling

Probable LBNL Areas

N/A

Focus Areas

Example Priorities:
  • Understanding how Parkinson’s disease biological and clinical heterogeneity impacts disease presentation, clinical course and therapeutic outcomes, from prodromal to late-stage Parkinson’s disease
  • Development and characterization of in vitro model systems that approximate in vivo cellular and system complexity
  • Biological mechanisms or biomarkers, such as clinical, fluid, imaging, tissue, and devices, of unmet medical needs that could lead to the development of treatments for PD. Applications can utilize laboratory models through to human participants. Examples of unmet medical needs of interest include, but are not limited to: ○ Non-motor symptoms: – Autonomic – Cognitive – Fatigue – Olfaction – Pain – Psychiatric – Sensory – Sleep and circadian rhythm disruptions ○ Motor symptoms – Dyskinesia – Dystonia – Gait and balance – Tremor
  • Interventions that address unmet medical needs of PD that include both clinical and preclinical models. Examples of interventions of interest include, but are not limited to: ○ Biological ○ Pharmacological ○ Non-pharmacological ○ Surgical ○ Non-surgical devices ○ Non-invasive central nervous system stimulation
Specific Technical Skills:
Understanding how Parkinson’s disease biological and clinical heterogeneity impacts disease presentation, clinical course and therapeutic outcomes, from prodromal to late-stage Parkinson’s diseaseDevelopment and characterization of in vitro model systems that approximate in vivo cellular and system complexityBiological mechanisms or biomarkers, such as clinical, fluid, imaging, tissue, and devices, of unmet medical needs that could lead to the development of treatments for PD. Applications can utilize laboratory models through to human participants. Examples of unmet medical needs of interest include, but are not limited to: ○ Non-motor symptoms: – Autonomic – Cognitive – Fatigue – Olfaction – Pain – Psychiatric – Sensory – Sleep and circadian rhythm disruptions ○ Motor symptoms – Dyskinesia – Dystonia – Gait and balance – TremorInterventions that address unmet medical needs of PD that include both clinical and preclinical models. Examples of interventions of interest include, but are not limited to: ○ Biological ○ Pharmacological ○ Non-pharmacological ○ Surgical ○ Non-surgical devices ○ Non-invasive central nervous system stimulation
Potential PIs for this Area:
NameScoreOrganization

Potential LBNL PIs (Overall)

Note on PI Matching: These suggestions are generated through an AI-driven semantic analysis of LBNL staff profiles.

NameScoreOrganization
Kevin Fan0.74LD | LD | Strategic Partnerships · Neuroimaging Techniques
Jian-Hua Mao0.74BSA | Biological Systems & Engineering | Department of BioEngineering and BioMedical Sciences · Biomarker Discovery and Validation
Jennifer Rosenbluth0.73 · In Vitro Disease Modeling
Karthik Shekhar0.72BSA | Biological Systems & Engineering | Biodesign Dept · Parkinson's Disease Heterogeneity
Zixi Hu0.71CSA | AMCR | Mathematics · Biostatistical Analysis and Modeling
Aris Polyzos0.71BSA | Molecular Biophysics & Integrated Bioimaging | Cellular & Tissue Image · Animal Models of Neurodegeneration
Josh North0.71EESA | CESD | Earth System Sciences · Clinical Course Analysis
Gerard Marriott0.70BSA | Molecular Biophysics & Integrated Bioimaging | Cellular & Tissue Image · Pharmacological Interventions
Christoph Kirst0.70CSA | SciData | Data & Computational Science · Central Nervous System Stimulation
Eleanor Zizka0.69BSA | Biological Systems & Engineering | Department of BioEngineering and BioMedical Sciences · Non-Pharmacological Interventions

Fundamental Research Exemption (FRE)

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities.